Autres langues Monte Rosa Therapeutics, Inc.

Actions

GLUE

US61225M1027

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 15/05/2024			Varia. 5j.	Varia. 1 janv.
5,23 ^USD	+4,60%		-0,57%	-7,43%

09/05	Monte Rosa Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
02/05	Monte Rosa Therapeutics, Inc. annonce le départ d'Owen Wallace en tant que directeur scientifique et la transition vers un poste de membre de son conseil consultatif scientifique	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants	15/05
Monte Rosa Therapeutics : Corporate Presentation - May 2024	09/05
Monte Rosa Therapeutics: Q1 Earnings Snapshot	09/05
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update	09/05
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer	02/05
Monte Rosa Therapeutics, Inc. Announces Departure of Owen Wallace as Chief Scientific Officer and Transition to Member of its Scientific Advisory Board	02/05
Monte Rosa Therapeutics : AACR 2024 – The GSPT1 Molecular Glue Degrader MRT-2359 Is Active against Prostate Cancer	03/04
Monte Rosa Therapeutics Q4 Net Loss Narrows; Shares Decline	14/03
Monte Rosa Therapeutics: Q4 Earnings Snapshot	14/03
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	14/03
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor	11/03
Monte Rosa Therapeutics, Inc. Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1b Pathway Inhibitor	11/03
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences	31/01
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024	08/01
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from NASDAQ Biotechnology Index	15/12
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference	21/11
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Monte Rosa Therapeutics, Inc.

Actions

GLUE

US61225M1027

Autres langues

Filtres